PharmaCyte Biotech develops and commercializes cellular therapies for cancer, diabetes, and malignant ascites using a proprietary cellulose-based technology called Cell-in-a-Box. Their therapies include treatments for advanced and inoperable pancreatic cancer, encapsulated genetically modified insulin-producing cells for Type 1 and insulin-dependent Type 2 diabetes, and therapies for cancer based on cannabis plant constituents. PharmaCyte Biotech holds research agreements with the University of Technology in Sydney and the University of Northern Colorado and is based in Las Vegas, Nevada.